IL6 and metabolic syndrome: A recent 2022 study by Littman et al. demonstrated that cancer patients undergoing chemotherapy had elevated levels of TNF-α and IL-6, which were directly linked to increased insulin resistance and dyslipidemia [21]. While the activation of NF-κB is well-documented, further research should aim to understand the temporal dynamics of this activation and its long-term consequences.